Quarterly ResultAug 5, 2026, 04:23 PM

RxSight Q2 Revenue $33.7M; Net Loss $(12.1)M; Withdraws 2026 Guidance

AI Summary

RxSight, Inc. reported Q2 2026 total revenue of $33.7 million, which included $6.5 million from its strategic collaboration with Alcon. Product sales decreased by 19% year-over-year to $27.2 million, reflecting competitive pressures. The company posted a net loss of $(12.1) million, or $(0.29) per share, and an adjusted net loss of $(4.6) million, or $(0.11) per share. RxSight also announced the appointment of Aziz Mottiwala as its new President and CEO, and in connection with this leadership transition, withdrew its 2026 financial guidance, planning to resume formal guidance in early 2027.

Key Highlights

Q2 2026 total revenue was $33.7 million, including $6.5 million from Alcon collaboration.
Q2 2026 product sales were $27.2 million, a 19% decrease from the prior-year period.
Q2 2026 net loss was $(12.1) million, or $(0.29) per basic and diluted share.
Q2 2026 adjusted net loss was $(4.6) million, or $(0.11) per basic and diluted share.
Cash, cash equivalents, and short-term investments totaled $208.8 million as of June 30, 2026.
Appointed Aziz Mottiwala as President and Chief Executive Officer.
Entered strategic collaboration with Alcon, including up to $200 million upfront and milestone payments.
Withdrew 2026 financial guidance, with formal guidance to resume in early 2027.

View SEC Filing

RXST

Ophthalmic Goods

RxSight, Inc.

Price Impact